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Summary.-The anti-tumour action of methylene dimethane sulphonate (MDMS)
has been further investigated in relation to its immunosuppressive properties.
Following a dose of 10 mg/kg, the proportion of permanent regressions of Yoshida
lymphosarcoma transplants is lower in animals treated during the first 5 days of
tumour growth. Re-implants on day 28 to those animals in which regression of
the tumour had occurred indicated that the immune response to the tumour increases
during the first 7 days of tumour growth.
Studies of the effect of MDMS on the primary antibody-forming cell response
of mice to sheep red cell antigens showed this drug to be an immunosuppressant
comparable in strength to x-radiation. MDMS given to rats prior to tumour
transplantation also acted as an immunosuppressant in this system resulting in
an increased rate of tumour growth. For both responses the maximum immuno-
suppressive effect was obtained when the interval between drug administration
and antigenic challenge was minimal.
METHYLENE dimethane sulphonate
(MDMS) has been shown (Fox and Jack-
son, 1965; Fox, 1969) to exert an excellent
anti-tumour action on the transplanted
Yoshida lymphosarcoma in the Wistar
rat. This tumour is equivalent to an
allograft system, but the host reaction
against the transplantation antigens, al-
though great, does not normally reject
the tumour which eventually kills the
animal. Although tumour-specific anti-
gens probably play a minor role in
determining the host reaction against it,
this system does provide a useful model
system to study the contribution of host
immunity to the chemotherapeutic effect
of an anti-tumour drug (Mihich, 1969).
The factors influencing drug-induced re-
mission have been reviewed by Goldin
(1969) and Mandel and Rall (1969).
The results of the present study
indicate that the effectiveness of MDMS
as an anti-tumour agent varies according
to the level of immunity developed in
the tumour-bearing host. We have also
found that MDMS like other members of
this series of bifunctional alkylating
agents (Berenbaum, Timmis and Brown,
1967) possesses immunosuppressive pro-
perties as well as tumour cytotoxicity and
the net effect of these two opposing
activities in terms of tumour regression,
depends on the time of MDMS administra-
tion relative to the time of tumour trans-
plantation.
MATERIALS AND METHODS
Methylene dimethane sulphonate was
prepared as previously described (Fox and
Jackson, 1965) and injected intraperitoneally
in physiological saline (2-5 mg/ml). All
solutions were prepared under chilled condi-
tions immediately before use to avoid break-
down ofthe drug due to hydrolysis.
For the tumour growth studies, female
Wistar rats (150-200 g, 8 to 10 weeks old)
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fed on a standard diet based on the Scottish
N.E. Agricultural Society recommendations
and water ad libitum were used. Small
pieces of tumour tissue (approximately
5 mm3) were transplanted subcutaneously
by trochar implantation into the flank of the
animal. The tumour volume was measured
as previously described (Fox, 1969) on
successive days of growth.
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Fic. 1. The effect on growth of the Yoshida
sarcoma of MDMS (10 mg/kg) administered
intraperitoneally on days 3, 5, 7, 9, 11
(A to E) following transplantation. The
letters above the abscissa indicate the
corresponding growth curves. The ordin-
ate is a caliper derived volume in ml.
For studies of the anti-sheep red cell
response, 12 to 14 week old (C3H x AKR)
Fl male mice were given a single intravenous
injection of 108 washed sheep red cells
(Burroughs Wellcome and Co.). Cells pro-
ducing 19S haemolytic anti-sheep red cell
antibody (PFC) were detected using the
method of Jerne, Nordin and Henry (1963).
Spleen cells were suspended in appropriate
volumes of cold Eagle's medium (Burroughs
Wellcome and Co.) buffered with 0-002M
Tris-HCl and assayed individually in plates
of agarose (L'Industrie Biologique Francaise,
France) made up in the same medium. Two
or 3 replicate plates were prepared from
each spleen and the geometric mean PFC
response per spleen calculated as described
previously (Gregory and Lajtha, 1970).
RESULTS
Action of MDMS on the Yoshida Tumour
at Different Stages of Growth and it8 Effect
onSubsequent HostSusceptibility toFurther
Tumour Challenge
A large number of rats were trans-
planted with Yoshida tumour tissue,
mixed at random and then separated
into 5 groups ofapproximately 20 animals
per group. The groups were then given
MDMS (1O mg/kg) at 3, 5, 7, 9, and 11
days respectively, post-tumour transplan-
tation and tumour volumes were measured
up to the 28th day. The pattern of
tumour regression obtained in each group
was similar (Fig. 1). However, only
those animals that showed no regrowth
of the tumour following the initial regres-
sion were used in the construction of
this figure. The number of animals in
each group excluded because of tumour
regrowth is indicated in Table I (Part 1).
It can be seen that, paradoxically,
animals treated 3 days after transplanta-
tion were less likely to show complete
regression of their tumours than animals
with much larger tumours (up to more
than 10 times larger) treated on the 5th
to 9th day. To determine whether this
variation in the effectiveness of MDMS
treatment could be related to a cor-
responding variation in the level of the
anti-tumour immunity developed in the
host, the tumour-free survivors in each
group were tested for their ability to
reject a second Yoshida tumour trans-
planted 28 days after receiving the first
transplant. Only 36% of the animals
whose initial tumours were allowed to
grow for 3 days prior to MDMS treatment
were sufficiently sensitized to prevent a
second transplant from becoming even
temporarily established (Table I, Part 2).
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TABLE 1.-Effect of MDMS (10 mg/kg) given at Various Intervals After Tumour
Implantation and Subsequent Host Immunity to Further Tumour Challenge
Day of treatment* . 3 . 5 . 7 . 9 . 11
Part 1
No. of animals implanted
Deaths from non-experimental causes
No. of animals whose tumours failed to regress completely
Part 2 (1st re-implant day 28)
No. of animals with progressive tumours
No. of animals with delayed regressive tumours
No. of animals with no tumours
Percentage " immune "
Part 3 (2nd re-implant-day 164)
No. of animals with progressive tumours
No. of animals with delayed regressive tumours
No. of animals with no tumours .
Percentage " immune "
. 20 . 20
.1 . 3
. 5 .1
5/14
4/14
5/14
36
0/9
2/9
7/9
77
0/16
1/16 ..
15/16
94
1/16
2/16
13/16
81
. 21 . 21 . 20
.1 . 2 .1
. 0 . 2 . 4
0/20 0/17
0/20 0/17
20/20 . 17/17
100 . 100
0/20
5/20
15/20
75
1/15
0/15
14/15
93
1/17 . 0/14
1/17 . 3/14
15/17 . 11/14
88 . 79
* Day of implantation of the first transplant = zero.
Part 1 shows the situation on day 28 following the initial implant and treatment.
Part 2 shows the situation following the rechallenge of those animals in Part 1 in which the tumour
had regressed. " Progressive " tumours are those which continued to grow nearly exponentially and
" delayed regressive " tumours are those which first grow to measurable volumes and within 2 to 3 weeks
decrease and disappear.
Part 3 shows the situation following a second reimplant of those animals in Part 2 in which the first
reimplant had regressed.
Longer exposure to the primary sensitizing
tumour prior to MDMS administration
resulted in an increasing percentage of
animals " immune " to the second trans-
plant.
Further challenge of these " immune
animals 4-5 months later revealed the
longevity of this anti-tumour immunity;
however, differences between the resistant
survivors of the first re-implants were not
detectable (Table I, Part 3).
Measurement of MDMS immunosuppres-
sion
The kinetics of the PFC response
obtained in mice injected with MDMS
(20 mg/kg) one day before immunization
with 108 sheep red cells is shown in
Fig. 2. We have consistently observed
that the general pattern of the PFC
response in MDMS treated mice remains
relatively unchanged, although the peak
of the response may be depressed (about
78% in the experiment shown in Fig. 2)
and may also be delayed depending on
the extent of immunosuppression.
Fig. 3 shows the immunosuppressive
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FIG. 2.-The time course of the splenic
plaque forming colony (PFC) response in
normal mice 0 0, and mice injected
with MDMS (20 mg/kg), 0 ----; 24
hours prior to immunization (8 mice per
point ±1 standard error of the mean).
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the dose response curve obtained. Using
the LD 50/30 dose as a basis for com-
parison, MDMS is virtually indistinguish-
able from x-rays in its immunosuppressive
activity (Gregory and Ebert, 1971).
It is unlikely that the development
ofanti-tumour immunity inratsimplanted
with Yoshida tumours would be affected
by MDMS in exactly the same way as
the PFC response of mice to a single
injection of sheep red cells. It seemed
reasonable, however, to expect that some
suppression would occur and as a result
cause tumours implanted after drug treat-
ment to grow faster than normal. Fig. 5
shows such an increase in tumour growth
in rats given MDMS (10 mg/kg) 2 to 24
hours before transplantation. Injection
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FIG. 3.-The relationship between the time
of MDMS treatment relative to the time
of immunization (day 0), and its effect on
the peak PFC response obtained (0 O)
peak values, 0-- -O day 4 values). The
peak response is shifted from day 4 to day
5 in mice treated from 2 days before to
1 day after immunization (Region A)
(4 mice per point).
effect of MDMS (20 mg/kg) as a function
of the interval between drug administra-
tion and immunization. In this experi-
ment groups of mice were given MDMS
at the times indicated and then injected
all together at time zero with 108 sheep
red cells. In each treatment group mice
were assayed for PFC on days 3, 4, and 5,
and the maximum count obtained during
this period was used to calculate the
per cent suppression (relative to untreated
immunized controls). The greatest im-
munosuppressive effect was seen when
MDMS was given close to the time of
immunization.
On the basis of this study MDMS
given 2 hours before immunization was
selected as the schedule for measuring
the effect of increasing doses of MDMS
on the peak PFC response. Fig. 4 shows
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FIG. 4.-The survival of PFC responsiveness
(based on peak response values) as a
function of the dose of MDMS injected,
MDMS given 2-5 hours prior to immuniza-
tion (2 experiments, 6-8 mice per point)
Do = 3 0 mg/kg. Dq = 17-7 mg/kg, the
" quasi-threshold " dose level which is
obtained by extrapolating the exponential
part of the survival curve to the 100%
survival level.
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FIG. 5.-The effect of MDMS pretreatment
on the Yoshicia tuimour growth rate.
The volume on days to 8 inclusive is
indicated for animals treated -2, -1,
-0 1 and on the day of the implantation.
of MDMS at earlier times had no detect-
able effect.
DISCUSSION
It is generally accepted that most if
not all tumours possess antigens which
may be recognized by the immunological
system of the tumour-bearing host. Evi-
dence that host-immune reactions may
contribute in a significant way to the
anti-tumour effectiveness of a given treat-
ment has also been reported (Mihich,
1967, 1969). The likelihood of a similar
explanation in the case of MDMS treated
rats bearing Yoshida sarcoma transplants
was suggested by the results of a previous
study (Fox, 1969) which showed that
permanent regression of well-established
(20-30 g) tumours was obtained following
a single injection of MDMS, in spite of
the presence of a relatively high propor-
tion of MDMS resistant cells in the
tumour cell population. The present
observation of an increasing tumour
sensitivity to MDMS during the first week
and a halfafter transplantation is unlikely
to be explained by metabolic changes in
the tumour cells. It is, however, a
finding consistent with the idea that the
complete elimination of the cells present
in even a small tumour by the dose of
MDMS used, is dependent on the co-opera-
tive action ofthe drug and ofthe immuno-
logical system of the tumour bearing host.
This interpretation is further supported
by the finding that administration of
MDMS to rats prior to transplantation
resulted in an increased rate of tumour
growth.
Comparison of this latter effect of
MDMS with its effect on the production
ofantibody-forming cells in mice following
immunization with sheep red cells shows
a similar relationship between immuno-
suppression and the interval between
MDMS administration and immunization.
Maximum effect was obtained in both
cases when this interval was minimal.
In this respect MDMS behaves like a
Class II or Class III agent according to
Makinodan's classification (Makinodan,
Santos and Quinn, 1970) and differs
markedly from other closely related mem-
bers of the same series of dialkane sul-
phonates (Berenbaum et al., 1967).
In view of the observed time depen-
dence of the immunosuppressive activity
of MDMS, the decreased effectiveness of
MDMS treatment given 3 days rather
than 5 or 7 days after transplantation
may be exaggerated by a different immu-
nosuppressive effect resulting from injec-
tion of the drug at these two different
times on a developing immune system.
Similarly, the acquisition by the rat of
an increasing capacity to reject tumour
cells following tumour transplantation
might occur more rapidly than the data
in Table I (Part 2) would seem to suggest.
Regardless of the suppressive effect
of 10 mg/kg ofMDMS on the development
of anti-tumour immune reactioiis, it is
clear that this activity is of minor impor-
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tance relative to its anti-tumour effective-
ness in this tumour-host system, since a
large proportion oftumours regress perma-
nently independently of when the drug
is given. It is interesting to note that
in spite of the evidence for the develop-
ment of a strong anti-tumour response
following transplantation, Yoshida tu-
mours rarely regress spontaneously. This
suggests that the cytotoxic effect of
MDMS (or its derivatives) on the tumour
cell population may potentiate the host's
immunological attack or vice versa. Such
a possibility underlines the importance
of considering immunosuppressive side-
effects in the chemotherapy of cancer in
man, even though overt signs of an
anti-tumour response are not readily
evident.
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